29.40

4.27% -1.31

After Hours: 29.40

Xenon Pharmaceuticals Inc (XENE)

Overview News Price History Option Chain Financials Discussions Forecast

Xenon Pharmaceuticals Inc stock is traded at $29.40, with a volume of 728.33K. It is down -4.27% in the last 24 hours and down -18.38% over the past month. Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Previous Close:

$30.71

Open:

$29.71

24h Volume:

728.33K

Relative Volume:

1.60

Market Cap:

$2.22B

Revenue:

$13.17M

Net Income/Loss:

$-199.06M

P/E Ratio:

-10.73

EPS:

-2.74

Net Cash Flow:

$-156.53M

1W Performance:

-14.19%

1M Performance:

-18.38%

6M Performance:

-27.82%

1Y Performance:

-30.35%

1-Day Range:

$29.20

$30.76

1-Week Range:

$29.20

$33.80

52-Week Range:

$29.20

$46.00

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name

Xenon Pharmaceuticals Inc

Sector

Healthcare (1171)

Industry

Biotechnology (673)

Phone

(604) 484-3300

Address

200 - 3650 GILMORE WAY, BURNABY

Employee

259

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

XENE's Discussions on Twitter

Compare XENE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XENE Xenon Pharmaceuticals Inc	29.40	2.22B	13.17M	-199.06M	-156.53M	-2.74
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jan-04-24	Initiated	Citigroup	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight
Dec-14-22	Initiated	Goldman	Buy
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight
Oct-19-22	Initiated	Raymond James	Outperform
Aug-29-22	Initiated	BofA Securities	Buy
Jul-21-22	Initiated	JP Morgan	Overweight
Oct-28-21	Initiated	RBC Capital Mkts	Outperform
Oct-02-20	Initiated	SVB Leerink	Outperform
Jul-21-20	Initiated	Needham	Buy
Jun-01-20	Resumed	Jefferies	Buy
Mar-25-20	Initiated	Wedbush	Outperform
Jan-08-20	Initiated	William Blair	Outperform
Sep-20-19	Initiated	Guggenheim	Buy
Aug-08-18	Reiterated	Stifel	Buy
Mar-13-17	Initiated	Jefferies	Buy
Oct-21-16	Initiated	Stifel	Buy
Sep-26-16	Initiated	Guggenheim	Buy
Apr-14-16	Reiterated	Jefferies	Buy
Oct-30-15	Resumed	Jefferies	Buy
Dec-02-14	Initiated	Canaccord Genuity	Buy

View All

Xenon Pharmaceuticals Inc Stock (XENE) Latest News

04:23 AM

Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data (NASDAQ:XENE) - Seeking Alpha

04:23 AM

09:57 AM

Xenon Slides Ahead of San Diego Concference - Baystreet.ca

09:57 AM

09:12 AM

Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025 - TipRanks

09:12 AM

08:54 AM

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 - The Manila Times

08:54 AM

08:30 AM

Breakthrough Epilepsy Drug Shows Remarkable 3-Year Efficacy Data - Stock Titan

08:30 AM

Apr 03, 2025

Investors Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World

Apr 03, 2025

Apr 01, 2025

Xenon Pharmaceuticals Enters Oversold Territory (XENE) - Nasdaq

Apr 01, 2025

Thrivent Financial for Lutherans Sells 12,394 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

Apr 01, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Apr 01, 2025

Mar 31, 2025

Teacher Retirement System of Texas Acquires 2,994 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

Mar 31, 2025

Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025

Mar 29, 2025

StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold - Defense World

Mar 29, 2025

Mar 25, 2025

Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR.com

Mar 25, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Swiss National Bank - Defense World

Mar 25, 2025

Mar 24, 2025

(XENE) Trading Advice - news.stocktradersdaily.com

Mar 24, 2025

Mar 23, 2025

Xenon Pharmaceuticals announces executive changes - MSN

Mar 23, 2025

Bank of New York Mellon Corp Sells 2,294 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

Mar 23, 2025

Mar 20, 2025

What is William Blair’s Estimate for XENE Q1 Earnings? - Defense World

Mar 20, 2025

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World

Mar 20, 2025

Mar 19, 2025

Xenon Pharmaceuticals at Stifel Forum: Strategic Advances in CNS By Investing.com - Investing.com Canada

Mar 19, 2025

Mar 16, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of “Buy” by Brokerages - Defense World

Mar 07, 2025

Mar 06, 2025

Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World

Mar 06, 2025

Mar 05, 2025

Xenon Pharmaceuticals appoints PwC as new auditor - Investing.com

Mar 05, 2025

Xenon Pharmaceuticals appoints PwC as new auditor By Investing.com - Investing.com South Africa

Mar 05, 2025

Mar 04, 2025

New KCNQ2/3 activators disclosed in Xenon Pharmaceuticals patents - BioWorld Online

Mar 04, 2025

Mar 03, 2025

Q1 Earnings Forecast for XENE Issued By HC Wainwright - Defense World

Mar 03, 2025

Equities Analysts Offer Predictions for XENE Q1 Earnings - Defense World

Mar 03, 2025

What is Leerink Partnrs’ Estimate for XENE Q1 Earnings? - Defense World

Mar 03, 2025

(XENE) On The My Stocks Page - Stock Traders Daily

Mar 03, 2025

Mar 02, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year Low – Time to Sell? - Defense World

Mar 02, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Earns “Outperform” Rating from William Blair - Defense World

Mar 02, 2025

Feb 28, 2025

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN

Feb 28, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat

Feb 28, 2025

HC Wainwright Has Pessimistic Outlook of XENE Q1 Earnings - MarketBeat

Feb 28, 2025

Strategic Growth Potential and Upcoming Catalysts Drive Buy Rating for Xenon Pharmaceuticals - TipRanks

Feb 28, 2025

Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush - TipRanks

Feb 28, 2025

Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025

RBC Capital Adjusts Xenon Pharmaceuticals Price Target to $58 From $56, Maintains OutperformSpeculative Risk Rating - MarketScreener

Feb 28, 2025

Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $60 From $67, Maintains Buy Rating - Marketscreener.com

Feb 28, 2025

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025